









Markets
/
Stocks
/
nasdaq-qttb
/

Q32 Bio Inc

QTTB

4.240USD

+0.370+9.56%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

52.17MMarket Cap

LossP/E TTM



Q32 Bio Inc

4.240

+0.370+9.56%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Q32 Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Q32 Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 134 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Q32 Bio Inc's Score

Industry at a Glance

Industry Ranking

134 / 392

Overall Ranking

276 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Q32 Bio Inc Highlights

StrengthsRisks

Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -1.25, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.92M shares, decreasing 36.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 321.05K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.333

Target Price

+181.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Q32 Bio Inc is 6.86, ranking 197 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.86

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Q32 Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Q32 Bio Inc is 6.18, ranking 319 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.25, which is -83.56% below the recent high of -0.21 and -1451.57% above the recent low of -19.38.

Score

Industry at a Glance

Previous score

6.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 134/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Q32 Bio Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 20.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.333

Target Price

+181.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Q32 Bio Inc

QTTB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Q32 Bio Inc is 6.45, ranking 243 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.84 and the support level at 3.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.08

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Neutral

RSI(14)

62.340

Neutral

STOCH(KDJ)(9,3,3)

53.287

Neutral

ATR(14)

0.365

Low Volatility

CCI(14)

189.951

Buy

Williams %R

37.398

Buy

TRIX(12,20)

0.872

Sell

StochRSI(14)

65.155

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.068

Buy

MA10

4.019

Buy

MA20

3.887

Buy

MA50

3.442

Buy

MA100

2.962

Buy

MA200

2.389

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Q32 Bio Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 64.40%, representing a quarter-over-quarter decrease of 7.63%. The largest institutional shareholder is The Vanguard, holding a total of 321.05K shares, representing 2.61% of shares outstanding, with 2.93% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

2.25M

Atlas Venture

2.09M

Abingworth Management Limited

1.10M

Acorn Capital Advisors, LLC

803.42K

The Vanguard Group, Inc.

Star Investors

295.41K

+9.64%

ARCH Venture Partners

320.48K

Monaco asset management S.A.M.

311.14K

-47.44%

Pfizer Inc

277.78K

Sanofi SA

244.08K

Bristol Myers Squibb

200.24K

-73.62%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Q32 Bio Inc is 1.24, ranking 337 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.18. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.